The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain

The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain

The recombinant zoster vaccine (RZV) is included in the Spanish National Immunisation Programme for adults 65 years of age (years), with a potential progressive catch-up program for adults 66–80 years, starting with 80 years. However, the risk of herpes zoster (HZ) increases significantly from 50 ye...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea García, Laura Amanda Vallejo-Aparicio, Rosario Cambronero Martinez
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Healthcare resource use
herpes zoster
postherpetic neuralgia
public health impact
recombinant zoster vaccine
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2366353
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items